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ABSTRACT
Introduction: The replenishment of skin lipids
depleted in the dry skin state is a desirable
therapeutic target to restore skin moisturiza-
tion; however, there is limited evidence
demonstrating the success of this approach
through the use of topical emollients. The pur-
pose of this study was to provide evidence of the
benefits of a cream and equivalent lotion con-
taining skin lipids in a multi-vesicular emulsion
for the management of dry skin. The hypothesis
was that the test cream and test lotion could
sustain skin moisturization for longer than
traditional emollients by sustainably delivering
skin lipids.
Methods: A double-blind intra-subject vehicle-
controlled single open-application test on the
lower legs in people with dry, atopic dermatitis
(atopic eczema)-prone, skin was conducted.
There were six treatment sites, three per lower
leg in each participant, which were treated with
the test cream, the test lotion, three reference
creams commonly prescribed in the UK and no
treatment as a control. After baseline measure-
ments of skin hydration, 100 ll of the test/ref-
erence creams was applied to each of the
relevant treatment sites (random site alloca-
tion). Following treatment, measurements of
skin hydration and scoring of visual dryness was
conducted at timed intervals (3, 6, 12 and 24 h
post-product application).
Results: The test cream and lotion both signif-
icantly increased skin hydration and reduced
skin dryness for at least 24 h following a single
application compared to a no treatment control
site. Compared to three reference emollient
creams the test cream and test lotion were the
only products capable of sustaining clinically
meaningful improvements in skin moisturiza-
tion for 24 h.
Conclusion: The sustained moisturization
imparted by the test products reduces the need
for frequent emollient application, often
requiring 3–4 applications per day for tradi-
tional emollients, and should reduce the high
burden of managing dry skin conditions like
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Key Summary Points
Why carry out this study?
Stratum corneum lipid replacement
therapy is a promising strategy for treating
dry skin conditions like atopic dermatitis.
Dry skin is a common condition, affecting
around 20% of children and 30–75% of
adults over the age of 60.
The aim was to provide evidence of the
benefits of a cream and equivalent lotion
containing skin lipids in a multi-vesicular
emulsion for the management of dry skin.
What was learned from the study?
In contrast to traditional emollients
currently prescribed for dry skin, which
require regular application 3–4 times per
day, the test products imparted sustained
moisturization lasting for more than 24 h.
Reducing the number of applications
required to keep the skin hydrated will
help lessen the high burden of managing
dry skin conditions.
INTRODUCTION
Ceramides, cholesterol and free fatty acids are
important constituents of the stratum corneum
(SC), the outermost layer of the skin. Filling the
space between the corneocytes they form a
highly ordered matrix, referred to as the lipid
lamellae, that forms an effective waterproof
barrier. The composition and structure of the
lipid lamellae is critically important to the per-
meability barrier function of the skin. Low SC
ceramide levels are associated with xerosis (skin
dryness) and reduced skin barrier function
[1, 2]. In the dry skin condition atopic der-
matitis/eczema (AD) there is a reduction in the
amount of total SC lipids owing to a significant
ceramide deficiency in both lesional and non-
lesional skin [3]. SC lipid insufficiency in heal-
thy infants is linked to decreased stratum cor-
neum hydration (SCH) [4]. SC lipid levels are
also reduced in people over the age of 60 com-
pared to young adults, and are associated with
the increased incidence of skin dryness in this
population [5–7]. Skin supplementation with
skin lipids, including ceramides, is therefore a
potentially important mechanism for support-
ing the skin’s barrier function and maintaining
normal SCH across the ages in the general
population [8].
Here we present the findings of the first
study in a program of work to establish the
effects of a ceramide-containing cream and
lotion on the skin, henceforth referred to as the
test cream (TC) and test lotion (TL). Both test
products contain a range of skin lipids, includ-
ing ceramides 1, 3 and 6-II, triglycerides (source
of fatty acids) and cholesterol, important for the
formation of the skin barrier. Together with the
humectant glycerol these active moisturizing
agents are delivered using a multi-vesicular
emulsion (MVE) controlled-release system.
Unlike traditional oil-in-water emulsions with
oil droplets dispersed in a continuous water
phase, MVE is comprised of multilayer concen-
tric spheres of emulsified oil and water sus-
pended in an aqueous medium. The
moisturizers within each layer are released
sequentially thereby prolonging the hydrating
effects of the MVE moisturizer compared to
traditional moisturizers [9, 10]. The National
Institute for Health and Care Excellence (NICE)
guidelines on the treatment of AD suggest
applying moisturizers four times per day, which
can be an onerous task. The MVE technology in
the test products is purported to deliver sus-
tainable hydration over an extended period and
so reduce the number of applications required
per day. The aim of this study was to determine
the duration of SCH imparted by the test
products and compare it with current ‘tradi-
tional’ moisturizers marketed for the treatment
of dry skin in the UK. The most common type of
emollient cream prescribed by the National
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Health Service (NHS) is the simple emollient
cream based upon paraffins (accounting for
37% of all prescriptions in 2018). Of this class of
emollient, we selected three reference products
that together represented 22.1% of emollient
cream prescriptions in this period.
METHODS
This study was conducted at the Sheffield Der-
matology Research, Skin Barrier Research Facil-
ity from May 2018 until June 2018. Recruitment
took place during April 2018. The University of
Sheffield Research Ethics Committee (UREC)
approved the study, under the project reference
018584. The study was performed in accordance
with the Helsinki Declaration of 1964, and its
later amendments, and all subjects provided
informed consent to participate.
Study Design
A double-blind intra-subject vehicle-controlled
single open-application test on the lower legs in
people with dry eczema-prone skin was con-
ducted. The lower legs were chosen because of
their increased propensity for skin dryness, and
were divided into six test sites (4 9 5 cm each)
on the lateral side of the tibia ridge. Each test
site received a single 100-ll application of either
the TC, the TL, the reference creams (vehicle
controls, see Table 1 for details) or no treatment
(no treatment control, NTC). Randomized site
allocation was utilized to minimize site-depen-
dent effects using a randomization list gener-
ated at www.randomisation.com. Product
identities were concealed from the investigator
and participant by assigning each a letter code
from A to F. The biophysical properties of the
test sites were determined before and at set time
points after treatment application. Participants
were asked to refrain from washing the test sites
until completion of the study.
Participants
A single cohort of volunteers with dry skin and
a predisposition to AD was recruited.
Recruitment was open to male and female vol-
unteers, who were recruited on a first come first
served basis, assuming they met the specified
criteria. Inclusion criteria included having a
self-reported history of AD defined by the UK
Working Party diagnostic criteria, having visibly
dry skin on the lower leg, SCH within the test
area measuring B 35 AU and being aged
18 years and over. Exclusion criteria included
currently undergoing, or requiring, active drug
treatment for AD; a known allergy/hypersensi-
tivity to any of the excipients of the trial
preparations; use of other topical products and/
or abrasive cleansers/treatments on the test sites
for 1 week prior to and throughout the study;
having perceptible differences between the
visual dryness scores of the test sites; dermatitis,
acne, suntan, hyperpigmentation, multiple
nevi, tattoos, blemishes or dense body hair in
the test areas; a condition that in the opinion of
the investigator contradicts participation in the
study; use of any medication that could inter-
fere with the trial aim (e.g. corticosteroids, cal-
cineurin inhibitors, methotrexate) 3 months
prior to the start of the study treatment and
throughout the study; current participation in
an interventional clinical trial. Informed con-
sent was obtained from each participant. All
participants received remuneration appropriate
for their involvement.
Objective Measurement of SCH
SCH was measured indirectly via the capaci-
tance method using a Corneometer CM825 (CK
electronic GmbH, Cologne, Germany). The
corneometer measures in arbitrary units (AU)
from 0 to 120; a reading of 0 is recorded when in
contact with a surface containing no water and
120 when in direct contact with water. Normal
skin typically displays SCH readings in the
region of 35 AU, with hydrated skin being
above 40 and dry skin below 30. Baseline mea-
surements were taken before product applica-
tion and at 3, 6, 12 and 24 h following product
application. All assessments were performed in
a room maintained at 21 ± 2 C and 38–50%
relative humidity. All test sites were
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acclimatised to room conditions for 20 min
before each assessment.
Visual Scoring of Dryness
Visual dryness was scored by two experienced
graders independently using the overall dry skin
score (ODS) for dryness where 0 is no dryness
and 4 is marked dryness (skin dominated by
large scales, advanced roughness, redness pre-
sent, eczematous changes and cracks). Scoring
was conducted before product application and
at 3, 6, 12 and 24 h following product
application.
Statistical Analysis
All data were analysed using Prism 7 (GraphPad
Software, La Jolla, USA). The primary outcome
was the difference in the change in objective
SCH 3, 6, 12 and 24 h after application between
treated sites and the NTC. The secondary out-
come was the difference in the change in visual
skin dryness 3, 6, 12 and 24 h after application
between treated sites and the NTC. The signifi-
cance threshold was p\0.05. Results are pre-
sented as mean ± standard error of the mean
(SEM) unless otherwise indicated. SCH data was
significance tested at each time point using a
repeated-measures one-way analysis of variance
(ANOVA) with a Dunnett’s post-test. The study
was powered (80%) to detect clinically relevant
differences in SCH of 5 units (sample size C 18),
which represents the shift in hydration
observed between inactive and active AD [11].
The secondary outcome of skin dryness score
was significance tested at each time point using
a Friedman test with Dunn’s post-test.
Table 1 Investigational products
Name (brand name) Manufacturer Ingredients (active moisturizing agents)
Test cream, TC (CeraVe
cream)
L’OREAL, Active
Cosmetics Division
Aqua/water, glycerin, cetearyl alcohol, caprylic/capric triglyceride, cetyl
alcohol, ceteareth-20, petrolatum, dimethicone, phenoxyethanol,
behentrimonium methosulfate, potassium phosphate,
ethylhexylglycerin, sodium lauroyl lactylate, disodium EDTA,
dipotassium phosphate, ceramide NP, ceramide AP,
phytosphingosine, cholesterol, xanthan gum, carbomer, sodium
hyaluronate, tocopherol, ceramide EOP
Test lotion, TL (CeraVe
lotion)
L’OREAL, Active
Cosmetics Division
Aqua/water, glycerin, caprylic/capric triglyceride, cetearyl alcohol, cetyl
alcohol, dimethicone, phenoxyethanol, polysorbate 20, ceteareth-20,
behentrimonium methosulfate, polyglyceryl-3 diisostearate, sodium
lauroyl lactylate, ethylhexylglycerin, potassium phosphate, disodium
EDTA, dipotassium phosphate, ceramide NP, ceramide AP,
phytosphingosine, cholesterol, xanthan gum, carbomer, sodium
hyaluronate, tocopherol, ceramide EOP
Reference cream 1, RC1
(Zerobase cream)
Thornton & Ross Ltd Purified water, liquid paraffin, white soft paraffin, cetostearyl alcohol,
cetomacrogol, sodium dihydrogen phosphate, chlorocresol,
phosphoric acid
Reference cream 2, RC2
(Epimax cream)
Dermato-Logical Purified water, white soft paraffin, liquid paraffin, polysorbate 60,
cetosteryl alcohol, phenoxyethanol
Reference cream 3, RC3
(Aquamax cream)
Intapharm
Laboratories
Purified water, white soft paraffin, cetostearyl alcohol, liquid paraffin,
polysorbate 60, phenoxyethanol
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RESULTS
A total of 26 volunteers consented to take part
in the study, 22 of which completed the study.
Of the remaining four participants, three were
screening failures and one was unavailable on
the study days. Four participants who success-
fully completed the trial had scores for visual
dryness and/or SCH at the baseline visit (which
was conducted on a separate occasion to the
screening visit) outside the criteria defined in
the protocol. Results are therefore presented for
all 22 participants who completed the trial (full
analysis set, FAS) and for the 18 participants
who completed the trial according to the pro-
tocol (per protocol set, PPS). There were no
other protocol deviations and no missing
values.
The demographic characteristics of the study
cohort are presented in Table 2. All 22 partici-
pants had a self-reported history of AD, but were
not currently undergoing active drug (i.e. anti-
inflammatory agent) treatment. As per protocol
the participants refrained from using emollient
products on the test sites for 1 week prior to the
first study visit and refrained from washing the
test sites from 12 h before the start of the test
until after the final measurements were taken.
No adverse events occurred during the conduct
of the study.
The effect of a single application of each
treatment on SCH and visual dryness over time
is presented in Figs. 1 and 2. The overall trend is
consistent between both analysis sets, with the
exception that the PPS displays a drier, less
hydrated, skin condition at baseline on average.
The subsequent analysis is presented for the PPS
only (and results were consistent with the FAS).
TC and TL were the only treatments found to
sustainably increase SCH by more than 5 AU
compared to the NTC (Fig. 1). The greatest
change in SCH was recorded 3 h after product
Table 2 Cohort demographics
Demographic Full analysis set (FAS) Per protocol set (PPS)
n 22 18
Age (mean) 41 ± 2.96 43 ± 3.33
Sex
Male 10 7
Female 12 11
Ethnicity
White 19 15
South Asian 2 2
Mixed 1 1
Fitzpatrick skin type (median) 2 (range 1–5) 3 (range 1–5)
Atopic dermatitis (AD)
Previously suffered from eczema but it is fully resolved 5/22 (23%) 5/18 (28%)
Currently suffer from eczema but my skin is currently clear 8/22 (36%) 6/18 (33%)
Currently suffer from eczema and it is currently active/visible 9/22 (41%) 7/18 (39%)
SCH 25.76 ± 1.81 23.31 ± 1.55
Dryness 1.59 (range 0–3) 1.83 (range 1–3)
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application with a mean increase from the NTC
of 13.95 ± 1.58 AU for the TC and
16.59 ± 1.98 AU for the TL. SCH remained ele-
vated, albeit to a decreasing extent, for 24 h,
whereupon the increase in SCH was 6.58 ± 0.77
and 6.82 ± 1.01 AU compared to the NTC for
the TC and TL respectively. In comparison, the
reference products all delivered marginal chan-
ges in SCH that reached maximum increases of
3.65 ± 1.21 after 6 h, 2.21 ± 0.98 after 6 h, and
1.75 ± 1.09 after 12 h compared to the NTC for
RC1, RC2 and RC3 respectively.
Visual dryness at baseline displayed good
correlation with SCH levels measured using the
corneometer, r = - 0.6151. A single point on
the 5-point visual scale corresponded to a
change in SCH of approximately 6.67 AU. All
treatments significantly reduced the appearance
of skin surface dryness compared to the NTC at
3, 6 and 12 h following application by compa-
rable levels (approximately 1 point). However,
differences in performance became apparent
after 24 h where only RC1, TC and TL were
associated with significant differences. Skin
dryness was 1.2 ± 1.0 on average at the NTC
site 24 h post-application, whereas sites treated
with the reference products displayed slightly
reduced mean scores for visual dryness at
1.0 ± 1.0, 0.9 ± 0.9, 0.9 ± 1.0 for RC1, RC2 and
RC3 respectively. Mean visual skin dryness at
sites treated with the TC and TL was lower still
at 0.8 ± 0.8 and 0.8 ± 0.8 respectively.
DISCUSSION
The TC and TL both delivered sustained clini-
cally relevant increases in SCH that lasted more
than 24 h following a single application. In
contrast the three reference products delivered
marginal changes which did not reach a clini-
cally significant level. A change in SCH of
5 units corresponds to the difference between
active and inactive AD at non-lesional sites [12].
A decrease of 7 units corresponds to the differ-
ence between mild and moderate AD or
between normal and intrinsic AD skin [13, 14].
A greater difference of 13 units is observed
between moderate and severe AD and between
the skin of intrinsic and extrinsic AD patients.
By increasing SCH by more than 6.5 units over a
24-h period following application, the TC and
TL deliver clinically relevant levels of skin
moisturization appropriate for the treatment of
AD.
The capacitance data is supported by the
visual dryness scores. Whilst the sensitivity of
the visual dryness scale is notably reduced, and
restricted to the superficial surface layers of the
SC compared to the hydration measurements (a
change in visual dryness corresponded to a
change in 6.67 AU SCH here), the findings
support a more efficacious and longer-lasting
moisturization effect of the test products com-
pared to two of the three reference products.
RC1 was also associated with a significantly
lower level of dryness 24 h following applica-
tion, albeit to a smaller extent than the test
products, but this was not supported by the SCH
data. As a result of the low sensitivity of the
visual dryness scores it was not possible to sep-
arate the effects of the treatments.
The findings of this study reflect those of a
previous study comparing the effects of a single
application of three other emollients; Aqueous
cream (AC), Diprobase cream (DC) and Dou-
blebase gel (DG) [12]. AC and DC are similar in
composition to the reference products tested
here. DG is distinct owing to the presence of the
active moisturizing agent glycerol in a gel base.
DG was significantly more hydrating than AC or
DC; however, none of the products tested
exhibited a sustained clinically meaningful
bFig. 1 Effect of the 6 treatment conditions on SCH
(primary analysis). Raw SCH over 24 h following a single
application is displayed for the FAS (a) and PPS (b).
Change in SCH from baseline is displayed for the PPS at
3- (c), 6- (d), 12- (e) and 24-h (f) post-treatment. Baseline
measurements (0 h) were taken immediately prior to
application of the investigational products. NTC, no
treatment control; TC, test cream; TL, test lotion; RC,
reference cream. Error bars (a and b) indicate SEM. Boxes
(c–f) indicate the median, 25th and 75th percentiles, with
‘?’ for the mean and whiskers indicating the minimum
and maximum. Asterisks indicate the results of a Dunnett’s
post-test comparing each treatment to the NTC
(*p\ 0.05, **p\ 0.01, ***p\ 0.001, ****p\ 0.0001)
Dermatol Ther (Heidelb)
Dermatol Ther (Heidelb)
effect lasting 24 h. There is moderate clinical
evidence that glycerol-containing moisturizers,
which impart greater increases in SCH, are more
clinically efficacious compared to non-glycerol-
containing moisturizers [15]. Whilst this
demonstrates the link between SCH and clinical
efficacy in treating AD, it does not explain the
longer-lasting effects of the test products here.
In addition to glycerol the test products contain
a range of skin lipids in an MVE vehicle. This
combination of skin lipids and glycerol signifi-
cantly increases moisturization potential above
that of glycerol alone (by more than twofold)
[16]. Moreover, MVE technology controls the
release of active agents to prolong their thera-
peutic effect [17]. To this end we show here that
the combination of glycerol and skin lipids in
an MVE vehicle significantly increase and pro-
long SCH compared to traditional emollients
without these ingredients.
The study is limited by its narrow focus on
moisturization potential after a single applica-
tion. Repeated applications are expected to
impart additive effects. Skin dryness measure-
ments are included to confirm capacitance
measurements of SCH. Such visual observations
are limited by their relative insensitivity and the
baseline level of dryness. The results can be
readily generalized to male and female adults
prone to AD with dry skin, and the effects of the
reference products in this population agree with
previously published reports [11, 12, 17]. The
ethnic diversity of the population was low, but
representative of the population engaging in
research locally. Our intention is to follow this
preliminary study with a vehicle-controlled trial
investigating the effects of a treatment regimen
with the TC on skin barrier structure and func-
tion, in a similar population stratified by age.
CONCLUSIONS
The findings of this study demonstrate the
superior moisturization activity of the test
products, and suggest a concordantly greater
clinical efficacy [15]. Importantly at this stage,
and consistent with our hypothesis, a sustained
effect on both hydration and skin dryness last-
ing more than 24 h is reported for the test
products, but not for any of the reference
products. This means that the health of the skin
can be improved with once-daily applications of
the test products as opposed to the 2–4 appli-
cations per day recommended for traditional
emollients [18]. As a result of the high volume
of prescriptions for traditional emollients, this
data suggests that many patients would benefit
from improved skin moisturization and reduced
therapeutic burden by switching to one of the
test products.
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